Carcinoma of the prostate (CaP) is now the #1 cancer in men and its #2 killer. While the tumor marker prostate specific antigen (PSA) has revolutionized diagnosis and therapy, PSA has also defined CaP's most unique and pressing issues: the tendency of CaP to almost exclusively metastasize to bone giving an osteoblastic response, and the inevitability fact that this initially androgen sensitive cancer becomes independent and therefore progresses and kills. The Project is divided into three subprojects and a technical core. The first project seeks to learn more about the mechanisms of CaP cell """"""""trafficking"""""""" to bone in men before and after therapies. The approach will entail performing reverse transcriptase-polymerase chain reaction (RT-PCR) assays on bone marrow aspirates initially to PSA and then to several other prostate specific markers (e.g. PSM, hK2). This investigation will describe the phenomenology of CaP cells in bone over time an therapy, and provide insight into the mechanisms for these bone events. The second project seeks to learn in the laboratory more about the mechanisms of CaP-bone interactions. The approach will be to examine in vitro and in vivo the influence of several factors in CaP cells that may """"""""allow"""""""" CaP bone implantation, growth, and/or the unique osteoblastic response. The factors will be examined including Cathepsin K, PSA, hK2, PSAM, bone morphogenic proteins, and urokinase-type plasminogen activators. The third project seeks to learn more about the molecular mechanisms of androgen independent (AI) regulation of the PSA gene. The approach will be to characterize further the transcriptional binding sites unrelated to the androgen response elements on the PSA promoter, pursue further the mechanisms of ligand-independent activation of the androgen receptor (AR), and examine in more detail the protein AR and non-AR regulators. This information will help understand the process of AI.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (M1))
Program Officer
Nyberg, Leroy M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Schools of Medicine
United States
Zip Code
Nguyen, Holly M; Corey, Eva (2011) Methodology to investigate androgen-sensitive and castration-resistant human prostate cancer xenografts in preclinical setting. Methods Mol Biol 776:295-312
Roudier, Martine P; Morrissey, Colm; True, Lawrence D et al. (2008) Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 180:1154-60
Pfitzenmaier, Jesco; Ellis, William J; Arfman, Edward W et al. (2006) Telomerase activity in disseminated prostate cancer cells. BJU Int 97:1309-13
Roudier, M P; True, L D; Vessella, R L et al. (2004) Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity. J Clin Pathol 57:321-3
Roudier, Martine P; Corey, Eva; True, Lawrence D et al. (2004) Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res 118:311-39
Brubaker, K D; Corey, E; Brown, L G et al. (2004) Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 91:151-60
Blaszczyk, Natalie; Masri, Bassam A; Mawji, Nasrin R et al. (2004) Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res 10:1860-9
Brubaker, K D; Vessella, R L; True, L D et al. (2003) Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 18:222-30
Chaib, Hassan; MacDonald, James W; Vessella, Robert L et al. (2003) Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors. Genes Chromosomes Cancer 37:306-13
Roudier, M P; Vesselle, H; True, L D et al. (2003) Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 20:171-80

Showing the most recent 10 out of 48 publications